Since 2017, Matt Might has served as Director of the Hugh Kaul Precision Medicine Institute at the University of Alabama at Birmingham (UAB). At UAB, Matt is the Hugh Kaul Endowed Chair of Precision Medicine, a Professor of Internal Medicine and a Professor of Computer Science.

At UAB, Dr. Might's NIH and philanthropically funded research focuses on precision prevention, diagnosis and therapeutics across rare disease, cancer and common/chronic conditions. A principal theme in his research is the use of computer and data science to enhance clinical and academic medicine. At UAB, Dr. Might's NIH and philanthropically funded research focuses on precision prevention, diagnosis and therapeutics across rare disease, cancer and common/chronic conditions. A principal theme in his research is the use of computer and data science to enhance clinical and academic medicine.

From 2016 to 2018, Dr. Might was a Strategist in the Executive Office of the President in The White House. At The White House, Dr. Might worked primarily on President Obama's Precision Medicine Initiative with both the NIH and the Department of Veterans Affairs. Prior to this role, Dr. Might was a faculty member in the Department of Biomedical Informatics at the Harvard Medical School. At Harvard, Dr. Might's research focuses on rare disease discovery and diagnosis, and on the development of personalized therapeutics for rare disease.

Dr. Might's journey from computer science to medicine has been inspired by his son Bertrand. In 2012, Bertrand became the first patient in the world to be diagnosed with NGLY1 deficiency, and this inspired Dr. Might to use social media to discover other patients and form a community. Through the community's efforts in science, two therapeutics for NGLY1 deficiency have been identified since its discovery, and more are under active development. Dr. Might is co-founder and Chief Scientific Officer of NGLY1.org, a non-profit dedicated to finding treatments for NGLY1 deficiency, and he is a co-founder and Scientific Advisor to Pairnomix, a start-up which identifies potential patient-specific therapies for rare disorders -- and genetic epilepsies in particular.